Stewardship / Resistance Scan for Jun 21, 2017

Stewardship in long-term care
Statement on antimicrobial products
Types of prescribers

Review identifies factors to boost stewardship in long-term care

A literature review of antimicrobial stewardship activities at long-term care facilities (LTCFs) that focused on workflow systems identified factors that were effective and possibly complementary, researchers reported yesterday in Clinical Infectious Diseases.

They noted that LTCFs face different antimicrobial stewardship challenges than hospitals do, and identifying the useful interventions is especially important, given Centers for Medicare and Medicaid Services (CMS) rule changes requiring antimicrobial stewardship activities in LTCFs.

Of 20 studies on antimicrobial stewardship interventions at LTCFs that met the research criteria, 5 were randomized controlled trials and 15 were quasi-experimental analyses.

The effective approaches they found included multidisciplinary education supported by enduring material, integrating pre-prescription data collection tools into nurses' workflow, integrating post-prescription recommendations into prescribers' workflow, and using infectious disease experts as external consultants.

Structured education that involves nurses, nurse assistants, and prescribers may be a feasible and practical strategy, especially when combined with comprehensive approaches, such as incorporating actionable items into pocket guides and posting educational materials in common areas, the team concluded. They noted that education alone might be enough to start antimicrobial stewardship, but it isn't enough to sustain it.

Communication between people with different roles at LTCFs seems vital, the experts wrote, and, ideally, tools supporting antimicrobial stewardship, especially gathering relevant clinical information before prescribing and fostering communication among staff, will become embedded in electronic medical record systems.
Jun 20 Clin Infect Dis abstract


Scientists, medical experts warn of antimicrobial chemical hazards

A statement signed by more than 200 scientists and medical professionals is calling on the international community to limit the production and use of triclosan and triclocarban, two antimicrobial ingredients widely used in over-the-counter antibacterial soaps and thousands of other consumer products.

The Florence Statement on Triclosan and Triclocarban, written in 2016 and published yesterday in Environmental Health Perspectives, says that continued use of the chemicals is concerning because peer-reviewed research has concluded that they are environmentally persistent endocrine disruptors that bioaccumulate in aquatic plants and organisms and have been associated with reproductive and developmental harm in animals. The authors also say there's no evidence that use of triclosan and triclocarban improves consumer health or prevents disease, and that overuse may contribute to antimicrobial resistance and may modify the microbiome.

"We therefore call on the international community to limit the production and use of triclosan and triclocarban and to question the use of other antimicrobials," the authors write.

In September 2016, the US Food and Drug Administration (FDA) banned triclosan and triclocarban, along with 17 other active antimicrobial agents used in consumer antiseptic washes, saying that manufacturers had not demonstrated that the ingredients are safe for long-term daily use or are more effective than plain soap and water in preventing illness or infection. The FDA gave manufacturers 1 year to phase out or reformulate products using the chemicals.

The FDA ban, however, does not apply to hand sanitizing gels, foams, or wipes and doesn't limit use of the chemicals in healthcare settings. In addition, the statement notes that many of the chemicals are still used in other consumer and building products.  The authors of the statement say the narrow scope of the FDA's ruling indicates that "existing regulatory practices are not sufficient to protect human and ecosystem health from adverse impacts of antimicrobial chemicals."

The statement urges governments, chemical and product manufacturers, and consumers to avoid use of triclosan, triclocarban, and other antimicrobial chemicals except where they provide an evidence-based health benefit, and to use safer alternatives that pose no risk to humans or ecosystems.
Jun 20 Environ Health Perspect statement

Study finds higher antibiotic prescribing in docs who dismiss risks

Physicians who perceive the risks posed by antibiotics as low are more likely to prescribe them than those who consider potential side effects to be a concern and understand the problem posed by antibiotic resistance, according to a study yesterday in the Journal of General Internal Medicine.

US investigators analyzed data on 2,874 patient visits involving an antibiotic prescription for pneumonia or upper respiratory tract infection in 2014 and 2015. The prescriptions were written by 69 emergency department clinicians, and prescribing rates ranged from 7% to 91%.

Clinicians who framed prescribing decisions as a choice between continued illness and possible benefit (a "why not take a risk?" gist) had higher rates of prescribing (odds ratio [OR], 1.28). In contrast, those who tended to agree with the "antibiotics may be harmful" gist were associated with about a 50% lower prescribing rate (OR, 0.81). (Using the "gist" approach to categorizing prescribers is based on what researchers call "fuzzy-trace theory.")

Study author Eili Klein, PhD, a fellow with the Center for Disease Dynamics, Economics & Policy (CDDEP) said in a CDDEP news release, "What's needed are interventions that change the mental calculus of clinicians. The 'just to be safe' mentality of many clinicians doesn't recognize the potential harms of antibiotic treatment or consider the further development of antimicrobial resistance."

"Interventions that explicitly focus on changing providers' gists, such as by emphasizing that even rare side effects can happen eventually, or that antibiotic resistance may hurt the patient in the event of a future illness, are more likely to be effective," added co-author David Broniatowski, PhD.
Jun 20 J Gen Intern Med study
Jun 21 CDDEP news release

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»


Unrestricted financial support provided by

Bentson Foundation 3MAccelerate DiagnosticsGilead 
Grant support for ASP provided by

  Become an underwriter»